Chondroitin-Glucosamine Reduced Pain in Knee Arthritis in RCT
Saturday, March 14, 2015 02:56 PM

A new randomized controlled clinical trial has provided some support for the suggestion raised in the 2008 Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) that glucosamine plus chondroitin sulfate might provide clinically significant pain relief for patients with moderate to severe knee osteoarthritis (OA) pain.

A combination glucosamine/chondroitin sulfate product produced a 50.1% decrease in Western Ontario and McMaster OA index (WOMAC) pain, which is comparable to the 50.2% decrease seen in patients randomly assigned to receive celecoxib.

Patients received either chondroitin sulfate 400 mg plus glucosamine hydrochloride 500 mg (CS+GH; Droglican, Bioibérica SA) three times a day or celecoxib 200 mg every day for 6 months.

The primary outcome was the mean decrease in WOMAC pain score at 6 months. The CS+GH group used more rescue medication during the first month of study, but rescue medication use was low and similar for both groups thereafter.

The authors conclude, "The MOVES trial found that a fixed-dose combination of chondroitin sulfate plus glucosamine has comparable efficacy to celecoxib in reducing pain in patients with [OA] of the knee with moderate-to-severe pain after 6 months of treatment. The reduction in pain was both clinically important and statistically significant (50% reduction in both groups), as was the improvement in stiffness (46.9% reduction with the combination vs 49.2% with celecoxib), and function (45.5% vs 46.4%, respectively).... These results both confirm and extend those from the GAIT study in patients with severe knee pain."